Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein (MHC-HM421T)
Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein (MHC-HM421T)
Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein (MHC-HM421T)
  • Express System: HEK293
  • Product Tag: C-His-Avi
  • Purity: > 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC
  • Activity: Immobilized Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 7.6ng/ml determined by ELISA (QC Test). See testing image for detail.
  • Amino Acid Range: Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
Catalog #MHC-HM421T
Regular price $750.00
/
Size

Order now, ships by:

Product Description
Recombinant Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin.It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide.
Product Background
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Product Category
Recombinant Protein
Target
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer
Synonyms
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
MHC Form
Tetramer
Allele
HLA-A*11:01
Accession
Species
Human
Biotinylated
no
Amino Acid Range
Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide
Molecular Weight
The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Activity
Immobilized Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 7.6ng/ml determined by ELISA (QC Test). See testing image for detail.
Product Tag
C-His-Avi
Express System
HEK293
Purity
> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC
Endotoxin
Less than 1EU per ug by the LAL method.
Form
Lyophilized
Shipping
Shipped at ambient temperature.
Formulation
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water.
Stability And Storage
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Immobilized Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 7.6ng/ml determined by ELISA (QC Test).
Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.
The purity of Human HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer is greater than 95% as determined by SEC-HPLC.

Have more questions?

Check out our Frequently Asked Questions page for more details about product specifications, ordering, and shipments.

Contact Us

support@kactusbio.us

Recently viewed